ID   CEL3_CUCEC              Reviewed;         442 AA.
AC   Q868M7;
DT   23-FEB-2022, integrated into UniProtKB/Swiss-Prot.
DT   01-JUN-2003, sequence version 1.
DT   03-AUG-2022, entry version 82.
DE   RecName: Full=Galactose/N-acetylgalactosamine-binding lectin CEL-III {ECO:0000305};
DE            Short=Gal/GalNAc-binding lectin CEL-III {ECO:0000305};
DE   AltName: Full=CEL-III {ECO:0000303|PubMed:27101707, ECO:0000303|PubMed:7798179};
DE   AltName: Full=Hemolytic lectin CEL-III {ECO:0000312|EMBL:BAC75827.1};
DE   AltName: Full=Lectin CEL-III {ECO:0000303|PubMed:17977832, ECO:0000303|PubMed:23583369};
DE   Flags: Precursor;
GN   Name=cel3 {ECO:0000312|EMBL:BAC75827.1};
OS   Cucumaria echinata (Sea cucumber).
OC   Eukaryota; Metazoa; Echinodermata; Eleutherozoa; Echinozoa; Holothuroidea;
OC   Dendrochirotacea; Dendrochirotida; Cucumariidae; Cucumaria.
OX   NCBI_TaxID=40245 {ECO:0000312|EMBL:BAC75827.1};
RN   [1] {ECO:0000312|EMBL:BAC75827.1}
RP   NUCLEOTIDE SEQUENCE [MRNA], PROTEIN SEQUENCE OF 11-24; 28-58; 63-100;
RP   102-103; 105-167; 173-259; 264-303 AND 403-442, MASS SPECTROMETRY, AND
RP   PYROGLUTAMATE FORMATION AT GLN-11.
RX   PubMed=10561549; DOI=10.1016/s0167-4838(99)00212-5;
RA   Nakano M., Tabata S., Sugihara K., Kouzuma Y., Kimura M., Yamasaki N.;
RT   "Primary structure of hemolytic lectin CEL-III from marine invertebrate
RT   Cucumaria echinata and its cDNA: structural similarity to the B-chain from
RT   plant lectin, ricin.";
RL   Biochim. Biophys. Acta 1435:167-176(1999).
RN   [2]
RP   PROTEIN SEQUENCE OF 158-167; 291-300 AND 294-302, FUNCTION, SUBUNIT,
RP   SUBCELLULAR LOCATION, TISSUE SPECIFICITY, DOMAIN, AND CIRCULAR DICHROISM
RP   ANALYSIS OF THE C-TERMINUS.
RX   PubMed=14561725; DOI=10.1093/jb/mvg157;
RA   Kouzuma Y., Suzuki Y., Nakano M., Matsuyama K., Tojo S., Kimura M.,
RA   Yamasaki T., Aoyagi H., Hatakeyama T.;
RT   "Characterization of functional domains of the hemolytic lectin CEL-III
RT   from the marine invertebrate Cucumaria echinata.";
RL   J. Biochem. 134:395-402(2003).
RN   [3]
RP   PROTEIN SEQUENCE OF 291-300, FUNCTION, COFACTOR, ACTIVITY REGULATION,
RP   SUBUNIT, SUBCELLULAR LOCATION, TISSUE SPECIFICITY, AND DOMAIN.
RX   PubMed=11471734; DOI=10.1271/bbb.65.1347;
RA   Sallay I., Tojo S., Nomiyama K., Kouzuma Y., Kimura M., Yamasaki N.;
RT   "Calcium ions stabilize a protein structure of hemolytic lectin CEL-III
RT   from marine invertebrate Cucumaria echinata.";
RL   Biosci. Biotechnol. Biochem. 65:1347-1352(2001).
RN   [4]
RP   FUNCTION, COFACTOR, AND ACTIVITY REGULATION.
RX   PubMed=7798179; DOI=10.1093/oxfordjournals.jbchem.a124495;
RA   Hatakeyama T., Kohzaki H., Nagatomo H., Yamasaki N.;
RT   "Purification and characterization of four Ca(2+)-dependent lectins from
RT   the marine invertebrate, Cucumaria echinata.";
RL   J. Biochem. 116:209-214(1994).
RN   [5]
RP   FUNCTION, ACTIVITY REGULATION, BIOPHYSICOCHEMICAL PROPERTIES, SUBUNIT, AND
RP   SUBCELLULAR LOCATION.
RX   PubMed=7876091; DOI=10.1074/jbc.270.8.3560;
RA   Hatakeyama T., Nagatomo H., Yamasaki N.;
RT   "Interaction of the hemolytic lectin CEL-III from the marine invertebrate
RT   Cucumaria echinata with the erythrocyte membrane.";
RL   J. Biol. Chem. 270:3560-3564(1995).
RN   [6]
RP   FUNCTION, BIOPHYSICOCHEMICAL PROPERTIES, SUBUNIT, SUBCELLULAR LOCATION,
RP   TISSUE SPECIFICITY, AND CIRCULAR DICHROISM ANALYSIS.
RX   PubMed=8663224; DOI=10.1074/jbc.271.28.16915;
RA   Hatakeyama T., Furukawa M., Nagatomo H., Yamasaki N., Mori T.;
RT   "Oligomerization of the hemolytic lectin CEL-III from the marine
RT   invertebrate Cucumaria echinata induced by the binding of carbohydrate
RT   ligands.";
RL   J. Biol. Chem. 271:16915-16920(1996).
RN   [7]
RP   FUNCTION, SUBUNIT, SUBCELLULAR LOCATION, TISSUE SPECIFICITY, AND MASS
RP   SPECTROMETRY.
RX   PubMed=9305736; DOI=10.1016/s0014-5793(97)00976-9;
RA   Fujisawa T., Kuwahara H., Hiromasa Y., Niidome T., Aoyagi H.,
RA   Hatakeyama T.;
RT   "Small-angle X-ray scattering study on CEL-III, a hemolytic lectin from
RT   Holothuroidea Cucumaria echinata, and its oligomer induced by the binding
RT   of specific carbohydrate.";
RL   FEBS Lett. 414:79-83(1997).
RN   [8]
RP   FUNCTION, COFACTOR, ACTIVITY REGULATION, BIOPHYSICOCHEMICAL PROPERTIES,
RP   SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY.
RX   PubMed=9058193; DOI=10.1093/oxfordjournals.jbchem.a021571;
RA   Hatakeyama T., Miyamoto Y., Nagatomo H., Sallay I., Yamasaki N.;
RT   "Carbohydrate-binding properties of the hemolytic lectin CEL-III from the
RT   holothuroidea Cucumaria echinata as analyzed using carbohydrate-coated
RT   microplate.";
RL   J. Biochem. 121:63-67(1997).
RN   [9]
RP   FUNCTION, ACTIVITY REGULATION, BIOPHYSICOCHEMICAL PROPERTIES, SUBCELLULAR
RP   LOCATION, TISSUE SPECIFICITY, AND BIOTECHNOLOGY.
RX   PubMed=9133626; DOI=10.1093/oxfordjournals.jbchem.a021622;
RA   Oda T., Tsuru M., Hatakeyama T., Nagatomo H., Muramatsu T., Yamasaki N.;
RT   "Temperature- and pH-dependent cytotoxic effect of the hemolytic lectin
RT   CEL-III from the marine invertebrate Cucumaria echinata on various cell
RT   lines.";
RL   J. Biochem. 121:560-567(1997).
RN   [10]
RP   FUNCTION, SUBUNIT, AND CIRCULAR DICHROISM ANALYSIS.
RX   PubMed=9692203; DOI=10.1271/bbb.62.1185;
RA   Hatakeyama T., Matsuyama Y., Funada T., Fukuyama S., Kuwahara H.,
RA   Aoyagi H., Yamasaki N.;
RT   "Chemical modification of the hemolytic lectin CEL-III by succinic
RT   anhydride: involvement of amino groups in the oligomerization process.";
RL   Biosci. Biotechnol. Biochem. 62:1185-1189(1998).
RN   [11]
RP   FUNCTION, AND BIOPHYSICOCHEMICAL PROPERTIES.
RX   PubMed=9805377; DOI=10.1271/bbb.62.1757;
RA   Sallay I., Hatakeyama T., Yamasaki N.;
RT   "Studies on the carbohydrate binding sites of the hemolytic lectin CEL-III
RT   isolated from the marine invertebrate Cucumaria echinata.";
RL   Biosci. Biotechnol. Biochem. 62:1757-1761(1998).
RN   [12]
RP   FUNCTION, ACTIVITY REGULATION, BIOPHYSICOCHEMICAL PROPERTIES, SUBUNIT,
RP   SUBCELLULAR LOCATION, TISSUE SPECIFICITY, AND CIRCULAR DICHROISM ANALYSIS.
RX   PubMed=10478454; DOI=10.1271/bbb.63.1279;
RA   Kouriki-Nagatomo H., Hatakeyama T., Jelokhani-Niaraki M., Kondo M.,
RA   Ehara T., Yamasaki N.;
RT   "Molecular mechanism for pore-formation in lipid membranes by the hemolytic
RT   lectin CEL-III from marine invertebrate Cucumaria echinata.";
RL   Biosci. Biotechnol. Biochem. 63:1279-1284(1999).
RN   [13]
RP   FUNCTION, AND BIOPHYSICOCHEMICAL PROPERTIES.
RX   PubMed=9990124; DOI=10.1093/oxfordjournals.jbchem.a022284;
RA   Hatakeyama T., Sato T., Taira E., Kuwahara H., Niidome T., Aoyagi H.;
RT   "Characterization of the interaction of hemolytic lectin CEL-III from the
RT   marine invertebrate, Cucumaria echinata, with artificial lipid membranes:
RT   involvement of neutral sphingoglycolipids in the pore-forming process.";
RL   J. Biochem. 125:277-284(1999).
RN   [14]
RP   FUNCTION, BIOPHYSICOCHEMICAL PROPERTIES, SUBUNIT, SUBCELLULAR LOCATION, AND
RP   TISSUE SPECIFICITY.
RX   PubMed=10101284; DOI=10.1093/oxfordjournals.jbchem.a022341;
RA   Oda T., Shinmura N., Nishioka Y., Komatsu N., Hatakeyama T., Muramatsu T.;
RT   "Effect of the hemolytic lectin CEL-III from Holothuroidea Cucumaria
RT   echinata on the ANS fluorescence responses in sensitive MDCK and resistant
RT   CHO cells.";
RL   J. Biochem. 125:713-720(1999).
RN   [15]
RP   FUNCTION, AND SUBUNIT.
RX   PubMed=10923802; DOI=10.1271/bbb.64.1278;
RA   Kuwahara H., Funada T., Hatakeyama T., Aoyagi H.;
RT   "Effects of chemical modification of carboxyl groups in the hemolytic
RT   lectin CEL-III on its hemolytic and carbohydrate-binding activities.";
RL   Biosci. Biotechnol. Biochem. 64:1278-1281(2000).
RN   [16]
RP   FUNCTION, SUBUNIT, AND CIRCULAR DICHROISM ANALYSIS.
RX   PubMed=11983084; DOI=10.1093/oxfordjournals.jbchem.a003161;
RA   Kuwahara H., Yamasaki T., Hatakeyama T., Aoyagi H., Fujisawa T.;
RT   "Oligomerization process of the hemolytic lectin CEL-III purified from a
RT   sea cucumber, Cucumaria echinata.";
RL   J. Biochem. 131:751-756(2002).
RN   [17]
RP   DOMAIN, BIOTECHNOLOGY, AND MUTAGENESIS OF LYS-342; VAL-344; LYS-348;
RP   VAL-351; VAL-353; LYS-354; VAL-355 AND LYS-361.
RX   PubMed=14999010; DOI=10.1093/jb/mvh007;
RA   Hatakeyama T., Suenaga T., Eto S., Niidome T., Aoyagi H.;
RT   "Antibacterial activity of peptides derived from the C-terminal region of a
RT   hemolytic lectin, CEL-III, from the marine invertebrate Cucumaria
RT   echinata.";
RL   J. Biochem. 135:65-70(2004).
RN   [18]
RP   FUNCTION, SUBCELLULAR LOCATION, TISSUE SPECIFICITY, AND BIOTECHNOLOGY.
RX   PubMed=18159942; DOI=10.1371/journal.ppat.0030192;
RA   Yoshida S., Shimada Y., Kondoh D., Kouzuma Y., Ghosh A.K.,
RA   Jacobs-Lorena M., Sinden R.E.;
RT   "Hemolytic C-type lectin CEL-III from sea cucumber expressed in transgenic
RT   mosquitoes impairs malaria parasite development.";
RL   PLoS Pathog. 3:e192-e192(2007).
RN   [19]
RP   DOMAIN, REGION, AND MUTAGENESIS OF VAL-332; VAL-334; VAL-336; VAL-351;
RP   VAL-353 AND VAL-355.
RX   PubMed=17965430; DOI=10.1093/jb/mvm195;
RA   Hisamatsu K., Tsuda N., Goda S., Hatakeyama T.;
RT   "Characterization of the {alpha}-helix region in domain 3 of the haemolytic
RT   lectin CEL-III: implications for self-oligomerization and haemolytic
RT   processes.";
RL   J. Biochem. 143:79-86(2008).
RN   [20]
RP   FUNCTION, COFACTOR, ACTIVITY REGULATION, REGION, AND CIRCULAR DICHROISM
RP   ANALYSIS.
RX   PubMed=19420692; DOI=10.1271/bbb.80793;
RA   Hisamatsu K., Unno H., Goda S., Hatakeyama T.;
RT   "Effects of Ca2+ on refolding of the recombinant hemolytic lectin CEL-
RT   III.";
RL   Biosci. Biotechnol. Biochem. 73:1203-1205(2009).
RN   [21]
RP   FUNCTION, SUBUNIT, MUTAGENESIS OF VAL-332; VAL-334; VAL-336; VAL-351;
RP   VAL-353 AND VAL-355, AND CIRCULAR DICHROISM ANALYSIS.
RX   PubMed=19356139; DOI=10.2174/092986609787848054;
RA   Hisamatsu K., Unno H., Goda S., Hatakeyama T.;
RT   "Roles of the valine clusters in domain 3 of the hemolytic lectin CEL-III
RT   in its oligomerization and hemolytic abilities.";
RL   Protein Pept. Lett. 16:411-414(2009).
RN   [22]
RP   FUNCTION, SUBUNIT, AND SUBCELLULAR LOCATION.
RX   PubMed=22313748; DOI=10.1271/bbb.110635;
RA   Shimizu Y., Yamazaki H., Yoshida S., Yonekura M., Kouzuma Y.;
RT   "Molecular cloning, functional expression, and characterization of
RT   isolectin genes of hemolytic lectin CEL-III from the marine invertebrate
RT   Cucumaria echinata.";
RL   Biosci. Biotechnol. Biochem. 76:276-282(2012).
RN   [23]
RP   FUNCTION, SUBUNIT, SUBCELLULAR LOCATION, TISSUE SPECIFICITY, AND
RP   CRYSTALLIZATION.
RX   PubMed=23545649; DOI=10.1107/s1744309113004065;
RA   Unno H., Hisamatsu K., Nagao T., Tateya Y., Matsumoto N., Goda S.,
RA   Hatakeyama T.;
RT   "Crystallization and preliminary crystallographic study of oligomers of the
RT   haemolytic lectin CEL-III from the sea cucumber Cucumaria echinata.";
RL   Acta Crystallogr. F 69:416-420(2013).
RN   [24]
RP   FUNCTION, SUBUNIT, MUTAGENESIS OF GLN-55; SER-315; SER-325; ILE-340;
RP   LYS-342; ILE-345; LYS-348; SER-350; LYS-354; VAL-355; SER-360; LYS-361;
RP   ASN-365; TYR-375; ASP-381; GLU-385; ARG-388; ASP-405; LEU-407; ILE-413;
RP   LYS-415; ARG-418; LYS-430 AND ASP-435, AND CIRCULAR DICHROISM ANALYSIS.
RX   PubMed=23583369; DOI=10.1016/j.bbagen.2013.04.010;
RA   Hisamatsu K., Nagao T., Unno H., Goda S., Hatakeyama T.;
RT   "Identification of the amino acid residues involved in the hemolytic
RT   activity of the Cucumaria echinata lectin CEL-III.";
RL   Biochim. Biophys. Acta 1830:4211-4217(2013).
RN   [25]
RP   FUNCTION, AND SUBUNIT.
RX   PubMed=23470749; DOI=10.1271/bbb.120981;
RA   Goda S., Sadakata H., Unno H., Hatakeyama T.;
RT   "Effects of detergents on the oligomeric structures of hemolytic lectin
RT   CEL-III as determined by small-angle X-ray scattering.";
RL   Biosci. Biotechnol. Biochem. 77:679-681(2013).
RN   [26]
RP   FUNCTION, AND MUTAGENESIS OF ASP-381 AND LYS-415.
RX   PubMed=27101707; DOI=10.1080/09168451.2016.1176520;
RA   Nagao T., Masaki R., Unno H., Goda S., Hatakeyama T.;
RT   "Effects of amino acid mutations in the pore-forming domain of the
RT   hemolytic lectin CEL-III.";
RL   Biosci. Biotechnol. Biochem. 80:1966-1969(2016).
RN   [27] {ECO:0007744|PDB:1VCL}
RP   X-RAY CRYSTALLOGRAPHY (1.70 ANGSTROMS) OF 11-442 IN COMPLEX WITH CALCIUM;
RP   CHLORIDE AND MAGNESIUM, FUNCTION, COFACTOR, SUBCELLULAR LOCATION, TISSUE
RP   SPECIFICITY, DOMAIN, PYROGLUTAMATE FORMATION AT GLN-11, AND DISULFIDE
RP   BONDS.
RX   PubMed=15194688; DOI=10.1074/jbc.m404065200;
RA   Uchida T., Yamasaki T., Eto S., Sugawara H., Kurisu G., Nakagawa A.,
RA   Kusunoki M., Hatakeyama T.;
RT   "Crystal structure of the hemolytic lectin CEL-III isolated from the marine
RT   invertebrate Cucumaria echinata: implications of domain structure for its
RT   membrane pore-formation mechanism.";
RL   J. Biol. Chem. 279:37133-37141(2004).
RN   [28] {ECO:0007744|PDB:2Z48, ECO:0007744|PDB:2Z49}
RP   X-RAY CRYSTALLOGRAPHY (1.70 ANGSTROMS) OF 11-442 IN COMPLEX WITH CALCIUM;
RP   MAGNESIUM; METHYL ALPHA-GALACTOSIDE AND N-ACETYLGALACTOSAMINE, FUNCTION,
RP   COFACTOR, DOMAIN, DISULFIDE BONDS, AND MUTAGENESIS OF TYR-26; ASP-33;
RP   ASP-53; GLN-54 AND GLN-55.
RX   PubMed=17977832; DOI=10.1074/jbc.m705604200;
RA   Hatakeyama T., Unno H., Kouzuma Y., Uchida T., Eto S., Hidemura H.,
RA   Kato N., Yonekura M., Kusunoki M.;
RT   "C-type lectin-like carbohydrate recognition of the hemolytic lectin CEL-
RT   III containing ricin-type -trefoil folds.";
RL   J. Biol. Chem. 282:37826-37835(2007).
RN   [29] {ECO:0007744|PDB:3W9T}
RP   X-RAY CRYSTALLOGRAPHY (2.90 ANGSTROMS) OF 11-442 IN COMPLEX WITH CALCIUM;
RP   MAGNESIUM; FRUCTOSE AND GALACTOSE, FUNCTION, COFACTOR, SUBUNIT, SUBCELLULAR
RP   LOCATION, TISSUE SPECIFICITY, AND DISULFIDE BONDS.
RX   PubMed=24652284; DOI=10.1074/jbc.m113.541896;
RA   Unno H., Goda S., Hatakeyama T.;
RT   "Hemolytic Lectin CEL-III Heptamerizes via a Large Structural Transition
RT   from alpha-Helices to a beta-Barrel during the Transmembrane Pore Formation
RT   Process.";
RL   J. Biol. Chem. 289:12805-12812(2014).
CC   -!- FUNCTION: Galactose/N-acetylgalactosamine (Gal/GalNAc)-binding lectin
CC       with hemolytic activity. Favors saccharides that have a beta-1,4
CC       linkage at the non-reducing end rather than saccharides having
CC       alpha-1,6 or alpha-1,4 linkages. Binds lactose, lactulose, GalNAc,
CC       galactosamine, methyl alpha-galactopyranoside, methyl beta-
CC       galactopyranoside, N-acetyllactosamine, p-nitrophenyl beta-D-
CC       galactopyranoside (pNP-Gal), p-nitrophenyl N-acetyl-beta-D-
CC       galactosaminide (pNP-GalNAc), asialofetuin, and human erythrocyte
CC       membrane lipids lactosyl ceramide (LacCer) and globoside
CC       globotetraosylceramide (Gb4Cer). Binds moderately to galactose,
CC       melibiose, raffinose, fucose, methyl alpha-galactoside and methyl beta-
CC       galactoside. Binds weakly to glucose, mannose and N-acetylglucosamine
CC       (GlcNAc) (PubMed:7798179, PubMed:7876091, PubMed:8663224,
CC       PubMed:9305736, PubMed:9058193, PubMed:9133626, PubMed:9692203,
CC       PubMed:9805377, PubMed:10478454, PubMed:9990124, PubMed:10101284,
CC       PubMed:10923802, PubMed:11471734, PubMed:11983084, PubMed:14561725,
CC       PubMed:15194688, PubMed:17977832, PubMed:23545649, PubMed:23583369,
CC       PubMed:23470749, PubMed:27101707, PubMed:24652284, PubMed:22313748,
CC       PubMed:19356139, PubMed:18159942, PubMed:19420692). Has hemolytic
CC       activity towards human (A, B and O-type), rabbit and rat erythrocytes,
CC       but not towards mouse, chicken or horse erythrocytes (PubMed:7798179,
CC       PubMed:7876091, PubMed:8663224, PubMed:9058193, PubMed:9692203,
CC       PubMed:9805377, PubMed:10923802, PubMed:11471734, PubMed:19420692,
CC       PubMed:19356139, PubMed:23583369, PubMed:27101707, PubMed:22313748,
CC       PubMed:10101284, PubMed:18159942). Forms ion-permeable transmembrane
CC       pores in the erythrocyte membrane as well as in artificial liposomes
CC       containing human erythrocyte membrane lipids LacCer, Gb4Cer and
CC       galactosyl ceramide (GalCer) leading to destruction of the membrane
CC       (PubMed:7876091, PubMed:9133626, PubMed:10478454, PubMed:9990124). Has
CC       hemagglutinating activity towards rabbit, human and rat erythrocytes,
CC       and at relatively high concentrations towards chicken and horse
CC       erythrocytes, but not towards mouse erythrocytes (PubMed:9692203,
CC       PubMed:9805377, PubMed:9990124, PubMed:10923802, PubMed:11471734,
CC       PubMed:14561725, PubMed:19420692, PubMed:7798179, PubMed:18159942). Has
CC       dose-dependent cytotoxic effect on Madin-Darby canine kidney (MDCK),
CC       African green monkey kidney (Vero) and human epithelia carcinoma (HeLa)
CC       cell lines, but Chinese hamster ovary (CHO), rat sarcoma (XC) and
CC       potoroo rat kangaroo kidney (PtK1) cells are highly resistant to the
CC       cytotoxic effect of this protein (PubMed:9133626, PubMed:10101284).
CC       Impairs malaria parasite development in malaria parasite infected
CC       transgenic A.stephensi mosquitoes expressing this protein specifically
CC       in their midguts. Binds to ookinetes and leads to strong dose-dependent
CC       inhibition of ookinete formation in vitro. Leads to severely impaired
CC       oocyst formation and significantly reduced sporozoite production of
CC       rodent malaria parasite P.berghei in the salivary glands of the
CC       transgenic mosquitoes. The parasite transmission to uninfected mice
CC       (vectorial competence) of these mosquitoes is significantly impaired.
CC       Leads also to severely impaired oocyst formation of human malaria
CC       parasite P.falciparum in transgenic mosquitoes fed on mature
CC       P.falciparum gametocyte cultures (PubMed:18159942). May be involved in
CC       defense mechanisms acting as a toxic protein to foreign microorganisms
CC       (PubMed:7876091, PubMed:9133626). May act in defense against predators
CC       (PubMed:24652284). {ECO:0000269|PubMed:10101284,
CC       ECO:0000269|PubMed:10478454, ECO:0000269|PubMed:10923802,
CC       ECO:0000269|PubMed:11471734, ECO:0000269|PubMed:11983084,
CC       ECO:0000269|PubMed:14561725, ECO:0000269|PubMed:15194688,
CC       ECO:0000269|PubMed:17977832, ECO:0000269|PubMed:18159942,
CC       ECO:0000269|PubMed:19356139, ECO:0000269|PubMed:19420692,
CC       ECO:0000269|PubMed:22313748, ECO:0000269|PubMed:23470749,
CC       ECO:0000269|PubMed:23545649, ECO:0000269|PubMed:23583369,
CC       ECO:0000269|PubMed:24652284, ECO:0000269|PubMed:27101707,
CC       ECO:0000269|PubMed:7798179, ECO:0000269|PubMed:7876091,
CC       ECO:0000269|PubMed:8663224, ECO:0000269|PubMed:9058193,
CC       ECO:0000269|PubMed:9133626, ECO:0000269|PubMed:9305736,
CC       ECO:0000269|PubMed:9692203, ECO:0000269|PubMed:9805377,
CC       ECO:0000269|PubMed:9990124}.
CC   -!- COFACTOR:
CC       Name=Ca(2+); Xref=ChEBI:CHEBI:29108;
CC         Evidence={ECO:0000269|PubMed:11471734, ECO:0000269|PubMed:15194688,
CC         ECO:0000269|PubMed:17977832, ECO:0000269|PubMed:19420692,
CC         ECO:0000269|PubMed:24652284, ECO:0000269|PubMed:7798179,
CC         ECO:0000269|PubMed:9058193};
CC       Note=Binds 5 calcium ions per subunit. {ECO:0000269|PubMed:15194688,
CC       ECO:0000269|PubMed:17977832, ECO:0000269|PubMed:24652284};
CC   -!- COFACTOR:
CC       Name=Mg(2+); Xref=ChEBI:CHEBI:18420;
CC         Evidence={ECO:0000269|PubMed:15194688, ECO:0000269|PubMed:17977832,
CC         ECO:0000269|PubMed:24652284};
CC       Note=Binds 2 magnesium ions per subunit. Magnesium is probably occupied
CC       in place of calcium as excess magnesium is used in the experiments.
CC       {ECO:0000269|PubMed:15194688, ECO:0000269|PubMed:17977832,
CC       ECO:0000269|PubMed:24652284};
CC   -!- ACTIVITY REGULATION: Ca(2+) is required for hemolytic activity and the
CC       activity increases with increasing calcium concentration. Hemolytic
CC       activity is inhibited by N-acetylgalactosamine (GalNAc), lactose,
CC       lactulose, galactosamine, dextran with molecular masses greater than 4
CC       kDa, to a lesser extent by inulin and only slightly by sucrose and
CC       melezitose, but not by glucose or mannose. The activity is abolished in
CC       the presence of 10 mM EDTA (PubMed:11471734, PubMed:19420692,
CC       PubMed:7798179, PubMed:9058193, PubMed:7876091). Lactose-binding
CC       increases with increasing calcium concentration, but calcium has no
CC       effect on hemagglutinating activity (PubMed:9058193, PubMed:11471734).
CC       Cytotoxic effect on Madin-Darby canine kidney (MDCK) cell line is
CC       strongly inhibited by galactose, lactose and N-acetylgalactosamine
CC       (GalNAc), but not by raffinose, N-acetylglucosamine (GlcNAc), glucose,
CC       mannose, ribose or sucrose (PubMed:9133626). Pore formation in
CC       artificial lactosyl ceramide (LacCer) or globotetraosylceramide
CC       (Gb4Cer) containing liposomes is strongly inhibited by lactose
CC       (PubMed:10478454). {ECO:0000269|PubMed:10478454,
CC       ECO:0000269|PubMed:11471734, ECO:0000269|PubMed:19420692,
CC       ECO:0000269|PubMed:7798179, ECO:0000269|PubMed:7876091,
CC       ECO:0000269|PubMed:9058193, ECO:0000269|PubMed:9133626}.
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       pH dependence:
CC         Optimum pH for hemolytic activity is 10. Hemolytic activity increases
CC         with increasing pH from pH 7 to pH 10, but almost no hemolytic
CC         activity is observed below pH 6.5 (PubMed:7876091, PubMed:8663224).
CC         Binds to lactose between pH 4-10 (PubMed:9058193, PubMed:9805377).
CC         Pore formation in artificial liposomes containing human erythrocyte
CC         membrane lipids lactosyl ceramide (LacCer) or globotetraosylceramide
CC         (Gb4Cer) increases with increasing pH (PubMed:10478454). Cytotoxic
CC         effect on Madin-Darby canine kidney (MDCK) cell line increases with
CC         increasing pH with maximal cytotoxicity at pH 10 at 4 degrees
CC         Celsius, but no significant pH effect is observed at 37 degrees
CC         Celsius (PubMed:9133626, PubMed:10101284).
CC         {ECO:0000269|PubMed:10101284, ECO:0000269|PubMed:10478454,
CC         ECO:0000269|PubMed:7876091, ECO:0000269|PubMed:8663224,
CC         ECO:0000269|PubMed:9058193, ECO:0000269|PubMed:9133626,
CC         ECO:0000269|PubMed:9805377};
CC       Temperature dependence:
CC         Optimum temperature for hemolytic activity is 10 degrees Celsius.
CC         Hemolytic activity decreases markedly with increasing temperature
CC         (PubMed:7876091). Binds to lactose between 5-40 degrees Celsius, with
CC         maximal binding around 10 degrees Celsius (PubMed:9058193). Pore
CC         formation in artificial liposomes containing human erythrocyte
CC         membrane lipids lactosyl ceramide (LacCer) or globotetraosylceramide
CC         (Gb4Cer) increases with increasing temperature (PubMed:9990124).
CC         Cytotoxic effect on African green monkey kidney (Vero) and
CC         Madin-Darby canine kidney (MDCK) cell lines increases with decreasing
CC         temperature (PubMed:9133626). {ECO:0000269|PubMed:7876091,
CC         ECO:0000269|PubMed:9058193, ECO:0000269|PubMed:9133626,
CC         ECO:0000269|PubMed:9990124};
CC   -!- SUBUNIT: Oligomerizes in the human and rabbit erythrocyte membranes
CC       (PubMed:7876091, PubMed:8663224, PubMed:9305736, PubMed:9692203,
CC       PubMed:10478454, PubMed:10101284, PubMed:10923802, PubMed:11471734,
CC       PubMed:11983084, PubMed:14561725, PubMed:19356139, PubMed:23545649,
CC       PubMed:23583369, PubMed:23470749, PubMed:24652284, PubMed:22313748).
CC       Oligomerization is induced by binding of beta-1,4-linked disaccharide
CC       ligands such as lactose, lactulose, N-acetyllactosamine and phenyl-
CC       beta-D-galactoside, but only a little by N-acetylgalactosamine and
CC       galactose, and not at all by melibiose in aqueous solution in the
CC       presence of high salt concentration and pH 10 (PubMed:8663224,
CC       PubMed:9305736, PubMed:11983084, PubMed:23545649, PubMed:23583369,
CC       PubMed:23470749, PubMed:24652284). Forms heptamers that assemble into
CC       larger 21mer oligomers, which may be inserted as a transmembrane pore
CC       to the erythrocyte membrane (PubMed:9305736, PubMed:11983084,
CC       PubMed:23545649, PubMed:23470749, PubMed:24652284).
CC       {ECO:0000269|PubMed:10101284, ECO:0000269|PubMed:10478454,
CC       ECO:0000269|PubMed:10923802, ECO:0000269|PubMed:11471734,
CC       ECO:0000269|PubMed:11983084, ECO:0000269|PubMed:14561725,
CC       ECO:0000269|PubMed:19356139, ECO:0000269|PubMed:22313748,
CC       ECO:0000269|PubMed:23470749, ECO:0000269|PubMed:23545649,
CC       ECO:0000269|PubMed:23583369, ECO:0000269|PubMed:24652284,
CC       ECO:0000269|PubMed:7876091, ECO:0000269|PubMed:8663224,
CC       ECO:0000269|PubMed:9305736, ECO:0000269|PubMed:9692203}.
CC   -!- SUBCELLULAR LOCATION: Secreted {ECO:0000269|PubMed:10101284,
CC       ECO:0000269|PubMed:10478454, ECO:0000269|PubMed:11471734,
CC       ECO:0000269|PubMed:14561725, ECO:0000269|PubMed:15194688,
CC       ECO:0000269|PubMed:18159942, ECO:0000269|PubMed:22313748,
CC       ECO:0000269|PubMed:24652284, ECO:0000269|PubMed:7876091,
CC       ECO:0000269|PubMed:8663224, ECO:0000269|PubMed:9058193,
CC       ECO:0000269|PubMed:9133626, ECO:0000269|PubMed:9305736}.
CC   -!- TISSUE SPECIFICITY: Expressed in body fluid (at protein level).
CC       {ECO:0000269|PubMed:10101284, ECO:0000269|PubMed:10478454,
CC       ECO:0000269|PubMed:11471734, ECO:0000269|PubMed:14561725,
CC       ECO:0000269|PubMed:15194688, ECO:0000269|PubMed:18159942,
CC       ECO:0000269|PubMed:24652284, ECO:0000269|PubMed:7876091,
CC       ECO:0000269|PubMed:8663224, ECO:0000269|PubMed:9058193,
CC       ECO:0000269|PubMed:9133626, ECO:0000269|PubMed:9305736}.
CC   -!- DOMAIN: The N-terminal part (1-293) is a carbohydrate recognition
CC       domain (CRD) having three ricin B-type lectin domains with two
CC       carbohydrate-binding domains (PubMed:14561725). The CRD domain
CC       comprises of residues 11-159 and 160-293 and each of them has a beta-
CC       trefoil fold (PubMed:15194688, PubMed:17977832). Total of five
CC       carbohydrate molecules are bound by the CRD domain (PubMed:17977832).
CC       The CRD domain is sufficient for N-acetylgalactosamine (GalNAc)-binding
CC       (PubMed:14561725, PubMed:17977832). The CRD domain has weak
CC       hemagglutinating activity towards rabbit erythrocytes in the presence
CC       or absence of Ca(2+), but it is abolished in the presence of 10 mM EDTA
CC       or by lactose (PubMed:14561725). {ECO:0000269|PubMed:14561725,
CC       ECO:0000269|PubMed:15194688, ECO:0000269|PubMed:17977832}.
CC   -!- DOMAIN: The C-terminal part (291-442) is essential for oligomerization
CC       (PubMed:11471734, PubMed:14561725, PubMed:17965430). Oligomerization of
CC       the C-terminal part is induced upon binding of lactose. This C-terminal
CC       part is able to cause hemagglutination of rabbit erythrocytes probably
CC       due to hydrophobic interaction of the oligomer with the membrane
CC       leading to formation of ion-permeable pores in the membrane.
CC       Hemagglutinating activity of it is not inhibited by lactose, it is
CC       enhanced by Ca(2+) and completetely abolished in the presence of 10 mM
CC       EDTA (PubMed:14561725). {ECO:0000269|PubMed:11471734,
CC       ECO:0000269|PubMed:14561725, ECO:0000269|PubMed:17965430}.
CC   -!- DOMAIN: C-terminal part (342-361) has antibacterial activity especially
CC       toward Gram-positive bacteria S.aureus IFO 12732, and to a lesser
CC       extent toward Gram-positive bacteria B.subtilis IFO 3134
CC       (PubMed:14999010, PubMed:17965430). Weak antibacterial activity toward
CC       Gram-negative bacteria P.aeruginosa ATCC 27853, and even weaker toward
CC       Gram-negative bacteria E.coli ATCC 43827. This C-terminal part disrupts
CC       the bacterial membrane leading to enhanced permeabilization of the
CC       bacterial membrane. It has membrane-permeabilizing activity also in
CC       artificial lipid vesicles (PubMed:14999010).
CC       {ECO:0000269|PubMed:14999010, ECO:0000269|PubMed:17965430}.
CC   -!- MASS SPECTROMETRY: Mass=47490; Method=MALDI; Note=The measured mass is
CC       that of the mature protein.; Evidence={ECO:0000269|PubMed:10561549,
CC       ECO:0000269|PubMed:9305736};
CC   -!- BIOTECHNOLOGY: May have potential as a tool for controlled
CC       permeabilization of cell membranes (PubMed:9133626). The C-terminal
CC       part (342-361) of this protein may be used to generate mutant peptides
CC       having increased antibacterial effect (PubMed:14999010). This protein
CC       may also be used for the generation of mosquitoes that are refractory
CC       to all species of human Plasmodium (PubMed:18159942).
CC       {ECO:0000305|PubMed:14999010, ECO:0000305|PubMed:18159942,
CC       ECO:0000305|PubMed:9133626}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AB109017; BAC75827.1; -; mRNA.
DR   PDB; 1VCL; X-ray; 1.70 A; A/B=11-442.
DR   PDB; 2Z48; X-ray; 1.70 A; A/B=11-442.
DR   PDB; 2Z49; X-ray; 1.95 A; A/B=11-442.
DR   PDB; 3W9T; X-ray; 2.90 A; A/B/C/D/E/F/G=11-442.
DR   PDBsum; 1VCL; -.
DR   PDBsum; 2Z48; -.
DR   PDBsum; 2Z49; -.
DR   PDBsum; 3W9T; -.
DR   SMR; Q868M7; -.
DR   CAZy; CBM13; Carbohydrate-Binding Module Family 13.
DR   TCDB; 1.C.96.1.1; the haemolytic lectin, cel-iii (cel-iii) family.
DR   UniLectin; Q868M7; -.
DR   EvolutionaryTrace; Q868M7; -.
DR   GO; GO:0005615; C:extracellular space; IDA:UniProtKB.
DR   GO; GO:0005509; F:calcium ion binding; IDA:UniProtKB.
DR   GO; GO:0042806; F:fucose binding; IDA:UniProtKB.
DR   GO; GO:0005534; F:galactose binding; IDA:UniProtKB.
DR   GO; GO:0030395; F:lactose binding; IDA:UniProtKB.
DR   GO; GO:0000287; F:magnesium ion binding; IDA:UniProtKB.
DR   GO; GO:1903777; F:melibiose binding; IDA:UniProtKB.
DR   GO; GO:0046871; F:N-acetylgalactosamine binding; IDA:UniProtKB.
DR   GO; GO:0043621; F:protein self-association; IDA:UniProtKB.
DR   GO; GO:0019731; P:antibacterial humoral response; IDA:UniProtKB.
DR   GO; GO:0019730; P:antimicrobial humoral response; IC:UniProtKB.
DR   GO; GO:0001906; P:cell killing; IDA:UniProtKB.
DR   GO; GO:0050829; P:defense response to Gram-negative bacterium; IDA:UniProtKB.
DR   GO; GO:0050830; P:defense response to Gram-positive bacterium; IDA:UniProtKB.
DR   GO; GO:0044179; P:hemolysis in another organism; IDA:UniProtKB.
DR   GO; GO:0051673; P:membrane disruption in another organism; IDA:UniProtKB.
DR   GO; GO:0035915; P:pore formation in membrane of another organism; IDA:UniProtKB.
DR   GO; GO:0034120; P:positive regulation of erythrocyte aggregation; IDA:UniProtKB.
DR   GO; GO:0051260; P:protein homooligomerization; IDA:UniProtKB.
DR   CDD; cd00161; RICIN; 2.
DR   Gene3D; 3.30.1750.10; -; 1.
DR   InterPro; IPR028988; CEL-III_C_sf.
DR   InterPro; IPR035992; Ricin_B-like_lectins.
DR   InterPro; IPR000772; Ricin_B_lectin.
DR   Pfam; PF00652; Ricin_B_lectin; 2.
DR   SMART; SM00458; RICIN; 2.
DR   SUPFAM; SSF111265; SSF111265; 1.
DR   SUPFAM; SSF50370; SSF50370; 2.
DR   PROSITE; PS50231; RICIN_B_LECTIN; 3.
PE   1: Evidence at protein level;
KW   3D-structure; Antibiotic; Antimicrobial; Calcium; Cytolysis;
KW   Direct protein sequencing; Disulfide bond; Hemolysis; Lectin; Magnesium;
KW   Metal-binding; Pyrrolidone carboxylic acid; Repeat; Secreted.
FT   PROPEP          1..10
FT                   /note="Removed in mature form"
FT                   /evidence="ECO:0000269|PubMed:10561549"
FT                   /id="PRO_0000454468"
FT   CHAIN           11..442
FT                   /note="Galactose/N-acetylgalactosamine-binding lectin CEL-
FT                   III"
FT                   /evidence="ECO:0000305|PubMed:10561549"
FT                   /id="PRO_0000454469"
FT   DOMAIN          28..102
FT                   /note="Ricin B-type lectin 1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00174"
FT   DOMAIN          115..245
FT                   /note="Ricin B-type lectin 2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00174"
FT   DOMAIN          261..293
FT                   /note="Ricin B-type lectin 3"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00174"
FT   REGION          11..304
FT                   /note="Has hemagglutinating activity towards rabbit
FT                   erythrocytes, but no hemolytic activity towards them"
FT                   /evidence="ECO:0000269|PubMed:19420692"
FT   REGION          294..442
FT                   /note="Has a strong tendency to self-associate leading to
FT                   formation of oligomers"
FT                   /evidence="ECO:0000269|PubMed:17965430"
FT   BINDING         19
FT                   /ligand="D-galactose"
FT                   /ligand_id="ChEBI:CHEBI:4139"
FT                   /evidence="ECO:0000269|PubMed:17977832,
FT                   ECO:0007744|PDB:2Z48"
FT   BINDING         33..36
FT                   /ligand="D-galactose"
FT                   /ligand_id="ChEBI:CHEBI:4139"
FT                   /evidence="ECO:0000269|PubMed:17977832,
FT                   ECO:0000269|PubMed:24652284, ECO:0007744|PDB:2Z48,
FT                   ECO:0007744|PDB:2Z49, ECO:0007744|PDB:3W9T"
FT   BINDING         33
FT                   /ligand="Ca(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29108"
FT                   /ligand_label="1"
FT                   /evidence="ECO:0000269|PubMed:15194688,
FT                   ECO:0000269|PubMed:17977832, ECO:0000269|PubMed:24652284,
FT                   ECO:0007744|PDB:1VCL, ECO:0007744|PDB:2Z48,
FT                   ECO:0007744|PDB:2Z49, ECO:0007744|PDB:3W9T"
FT   BINDING         34
FT                   /ligand="Ca(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29108"
FT                   /ligand_label="1"
FT                   /evidence="ECO:0000269|PubMed:15194688,
FT                   ECO:0000269|PubMed:17977832, ECO:0000269|PubMed:24652284,
FT                   ECO:0007744|PDB:1VCL, ECO:0007744|PDB:2Z48,
FT                   ECO:0007744|PDB:2Z49, ECO:0007744|PDB:3W9T"
FT   BINDING         36
FT                   /ligand="Ca(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29108"
FT                   /ligand_label="1"
FT                   /evidence="ECO:0000269|PubMed:15194688,
FT                   ECO:0000269|PubMed:17977832, ECO:0000269|PubMed:24652284,
FT                   ECO:0007744|PDB:1VCL, ECO:0007744|PDB:2Z48,
FT                   ECO:0007744|PDB:2Z49, ECO:0007744|PDB:3W9T"
FT   BINDING         42
FT                   /ligand="Mg(2+)"
FT                   /ligand_id="ChEBI:CHEBI:18420"
FT                   /ligand_label="1"
FT                   /evidence="ECO:0000269|PubMed:15194688,
FT                   ECO:0000269|PubMed:17977832, ECO:0000269|PubMed:24652284,
FT                   ECO:0007744|PDB:1VCL, ECO:0007744|PDB:2Z48,
FT                   ECO:0007744|PDB:2Z49, ECO:0007744|PDB:3W9T"
FT   BINDING         43
FT                   /ligand="Mg(2+)"
FT                   /ligand_id="ChEBI:CHEBI:18420"
FT                   /ligand_label="1"
FT                   /evidence="ECO:0000269|PubMed:15194688,
FT                   ECO:0000269|PubMed:17977832, ECO:0000269|PubMed:24652284,
FT                   ECO:0007744|PDB:1VCL, ECO:0007744|PDB:2Z48,
FT                   ECO:0007744|PDB:2Z49, ECO:0007744|PDB:3W9T"
FT   BINDING         49
FT                   /ligand="D-galactose"
FT                   /ligand_id="ChEBI:CHEBI:4139"
FT                   /evidence="ECO:0000269|PubMed:17977832,
FT                   ECO:0000269|PubMed:24652284, ECO:0007744|PDB:2Z48,
FT                   ECO:0007744|PDB:2Z49, ECO:0007744|PDB:3W9T"
FT   BINDING         53
FT                   /ligand="Ca(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29108"
FT                   /ligand_label="1"
FT                   /evidence="ECO:0000269|PubMed:15194688,
FT                   ECO:0000269|PubMed:17977832, ECO:0000269|PubMed:24652284,
FT                   ECO:0007744|PDB:1VCL, ECO:0007744|PDB:2Z48,
FT                   ECO:0007744|PDB:2Z49, ECO:0007744|PDB:3W9T"
FT   BINDING         82
FT                   /ligand="Mg(2+)"
FT                   /ligand_id="ChEBI:CHEBI:18420"
FT                   /ligand_label="1"
FT                   /evidence="ECO:0000269|PubMed:15194688,
FT                   ECO:0000269|PubMed:17977832, ECO:0000269|PubMed:24652284,
FT                   ECO:0007744|PDB:1VCL, ECO:0007744|PDB:2Z48,
FT                   ECO:0007744|PDB:2Z49, ECO:0007744|PDB:3W9T"
FT   BINDING         83
FT                   /ligand="Mg(2+)"
FT                   /ligand_id="ChEBI:CHEBI:18420"
FT                   /ligand_label="1"
FT                   /evidence="ECO:0000269|PubMed:15194688,
FT                   ECO:0000269|PubMed:17977832, ECO:0000269|PubMed:24652284,
FT                   ECO:0007744|PDB:1VCL, ECO:0007744|PDB:2Z48,
FT                   ECO:0007744|PDB:2Z49, ECO:0007744|PDB:3W9T"
FT   BINDING         117
FT                   /ligand="D-galactose"
FT                   /ligand_id="ChEBI:CHEBI:4139"
FT                   /evidence="ECO:0000269|PubMed:17977832,
FT                   ECO:0007744|PDB:2Z48"
FT   BINDING         131..134
FT                   /ligand="D-galactose"
FT                   /ligand_id="ChEBI:CHEBI:4139"
FT                   /evidence="ECO:0000269|PubMed:17977832,
FT                   ECO:0000269|PubMed:24652284, ECO:0007744|PDB:2Z49,
FT                   ECO:0007744|PDB:3W9T"
FT   BINDING         131
FT                   /ligand="Ca(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29108"
FT                   /ligand_label="2"
FT                   /evidence="ECO:0000269|PubMed:15194688,
FT                   ECO:0000269|PubMed:17977832, ECO:0000269|PubMed:24652284,
FT                   ECO:0007744|PDB:1VCL, ECO:0007744|PDB:2Z48,
FT                   ECO:0007744|PDB:2Z49, ECO:0007744|PDB:3W9T"
FT   BINDING         132
FT                   /ligand="Ca(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29108"
FT                   /ligand_label="2"
FT                   /evidence="ECO:0000269|PubMed:15194688,
FT                   ECO:0000269|PubMed:17977832, ECO:0000269|PubMed:24652284,
FT                   ECO:0007744|PDB:1VCL, ECO:0007744|PDB:2Z48,
FT                   ECO:0007744|PDB:2Z49, ECO:0007744|PDB:3W9T"
FT   BINDING         134
FT                   /ligand="Ca(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29108"
FT                   /ligand_label="2"
FT                   /evidence="ECO:0000269|PubMed:15194688,
FT                   ECO:0000269|PubMed:17977832, ECO:0000269|PubMed:24652284,
FT                   ECO:0007744|PDB:1VCL, ECO:0007744|PDB:2Z48,
FT                   ECO:0007744|PDB:2Z49, ECO:0007744|PDB:3W9T"
FT   BINDING         141
FT                   /ligand="Mg(2+)"
FT                   /ligand_id="ChEBI:CHEBI:18420"
FT                   /ligand_label="1"
FT                   /evidence="ECO:0000269|PubMed:15194688,
FT                   ECO:0000269|PubMed:17977832, ECO:0000269|PubMed:24652284,
FT                   ECO:0007744|PDB:1VCL, ECO:0007744|PDB:2Z48,
FT                   ECO:0007744|PDB:2Z49, ECO:0007744|PDB:3W9T"
FT   BINDING         144..147
FT                   /ligand="D-galactose"
FT                   /ligand_id="ChEBI:CHEBI:4139"
FT                   /evidence="ECO:0000269|PubMed:17977832,
FT                   ECO:0000269|PubMed:24652284, ECO:0007744|PDB:2Z49,
FT                   ECO:0007744|PDB:3W9T"
FT   BINDING         151
FT                   /ligand="Ca(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29108"
FT                   /ligand_label="2"
FT                   /evidence="ECO:0000269|PubMed:15194688,
FT                   ECO:0000269|PubMed:17977832, ECO:0000269|PubMed:24652284,
FT                   ECO:0007744|PDB:1VCL, ECO:0007744|PDB:2Z48,
FT                   ECO:0007744|PDB:2Z49, ECO:0007744|PDB:3W9T"
FT   BINDING         178..181
FT                   /ligand="D-galactose"
FT                   /ligand_id="ChEBI:CHEBI:4139"
FT                   /evidence="ECO:0000269|PubMed:17977832,
FT                   ECO:0000269|PubMed:24652284, ECO:0007744|PDB:2Z49,
FT                   ECO:0007744|PDB:3W9T"
FT   BINDING         178
FT                   /ligand="Ca(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29108"
FT                   /ligand_label="3"
FT                   /evidence="ECO:0000269|PubMed:15194688,
FT                   ECO:0000269|PubMed:17977832, ECO:0000269|PubMed:24652284,
FT                   ECO:0007744|PDB:1VCL, ECO:0007744|PDB:2Z48,
FT                   ECO:0007744|PDB:2Z49, ECO:0007744|PDB:3W9T"
FT   BINDING         179
FT                   /ligand="Ca(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29108"
FT                   /ligand_label="3"
FT                   /evidence="ECO:0000269|PubMed:15194688,
FT                   ECO:0000269|PubMed:17977832, ECO:0000269|PubMed:24652284,
FT                   ECO:0007744|PDB:1VCL, ECO:0007744|PDB:2Z48,
FT                   ECO:0007744|PDB:2Z49, ECO:0007744|PDB:3W9T"
FT   BINDING         181
FT                   /ligand="Ca(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29108"
FT                   /ligand_label="3"
FT                   /evidence="ECO:0000269|PubMed:15194688,
FT                   ECO:0000269|PubMed:17977832, ECO:0000269|PubMed:24652284,
FT                   ECO:0007744|PDB:1VCL, ECO:0007744|PDB:2Z48,
FT                   ECO:0007744|PDB:2Z49, ECO:0007744|PDB:3W9T"
FT   BINDING         187
FT                   /ligand="Mg(2+)"
FT                   /ligand_id="ChEBI:CHEBI:18420"
FT                   /ligand_label="2"
FT                   /evidence="ECO:0000269|PubMed:15194688,
FT                   ECO:0000269|PubMed:17977832, ECO:0000269|PubMed:24652284,
FT                   ECO:0007744|PDB:1VCL, ECO:0007744|PDB:2Z48,
FT                   ECO:0007744|PDB:2Z49, ECO:0007744|PDB:3W9T"
FT   BINDING         188
FT                   /ligand="Mg(2+)"
FT                   /ligand_id="ChEBI:CHEBI:18420"
FT                   /ligand_label="2"
FT                   /evidence="ECO:0000269|PubMed:15194688,
FT                   ECO:0000269|PubMed:17977832, ECO:0000269|PubMed:24652284,
FT                   ECO:0007744|PDB:1VCL, ECO:0007744|PDB:2Z48,
FT                   ECO:0007744|PDB:2Z49, ECO:0007744|PDB:3W9T"
FT   BINDING         191..194
FT                   /ligand="D-galactose"
FT                   /ligand_id="ChEBI:CHEBI:4139"
FT                   /evidence="ECO:0000269|PubMed:17977832,
FT                   ECO:0000269|PubMed:24652284, ECO:0007744|PDB:2Z49,
FT                   ECO:0007744|PDB:3W9T"
FT   BINDING         198
FT                   /ligand="Ca(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29108"
FT                   /ligand_label="3"
FT                   /evidence="ECO:0000269|PubMed:15194688,
FT                   ECO:0000269|PubMed:17977832, ECO:0000269|PubMed:24652284,
FT                   ECO:0007744|PDB:1VCL, ECO:0007744|PDB:2Z48,
FT                   ECO:0007744|PDB:2Z49, ECO:0007744|PDB:3W9T"
FT   BINDING         219..222
FT                   /ligand="D-galactose"
FT                   /ligand_id="ChEBI:CHEBI:4139"
FT                   /evidence="ECO:0000269|PubMed:17977832,
FT                   ECO:0000269|PubMed:24652284, ECO:0007744|PDB:2Z49,
FT                   ECO:0007744|PDB:3W9T"
FT   BINDING         219
FT                   /ligand="Ca(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29108"
FT                   /ligand_label="4"
FT                   /evidence="ECO:0000269|PubMed:15194688,
FT                   ECO:0000269|PubMed:17977832, ECO:0000269|PubMed:24652284,
FT                   ECO:0007744|PDB:1VCL, ECO:0007744|PDB:2Z48,
FT                   ECO:0007744|PDB:2Z49, ECO:0007744|PDB:3W9T"
FT   BINDING         220
FT                   /ligand="Ca(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29108"
FT                   /ligand_label="4"
FT                   /evidence="ECO:0000269|PubMed:15194688,
FT                   ECO:0000269|PubMed:17977832, ECO:0000269|PubMed:24652284,
FT                   ECO:0007744|PDB:1VCL, ECO:0007744|PDB:2Z48,
FT                   ECO:0007744|PDB:2Z49, ECO:0007744|PDB:3W9T"
FT   BINDING         222
FT                   /ligand="Ca(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29108"
FT                   /ligand_label="4"
FT                   /evidence="ECO:0000269|PubMed:15194688,
FT                   ECO:0000269|PubMed:17977832, ECO:0000269|PubMed:24652284,
FT                   ECO:0007744|PDB:1VCL, ECO:0007744|PDB:2Z48,
FT                   ECO:0007744|PDB:2Z49, ECO:0007744|PDB:3W9T"
FT   BINDING         228
FT                   /ligand="Mg(2+)"
FT                   /ligand_id="ChEBI:CHEBI:18420"
FT                   /ligand_label="2"
FT                   /evidence="ECO:0000269|PubMed:15194688,
FT                   ECO:0000269|PubMed:17977832, ECO:0000269|PubMed:24652284,
FT                   ECO:0007744|PDB:1VCL, ECO:0007744|PDB:2Z48,
FT                   ECO:0007744|PDB:2Z49, ECO:0007744|PDB:3W9T"
FT   BINDING         229
FT                   /ligand="Mg(2+)"
FT                   /ligand_id="ChEBI:CHEBI:18420"
FT                   /ligand_label="2"
FT                   /evidence="ECO:0000269|PubMed:15194688,
FT                   ECO:0000269|PubMed:17977832, ECO:0000269|PubMed:24652284,
FT                   ECO:0007744|PDB:1VCL, ECO:0007744|PDB:2Z48,
FT                   ECO:0007744|PDB:2Z49, ECO:0007744|PDB:3W9T"
FT   BINDING         232..235
FT                   /ligand="D-galactose"
FT                   /ligand_id="ChEBI:CHEBI:4139"
FT                   /evidence="ECO:0000269|PubMed:17977832,
FT                   ECO:0000269|PubMed:24652284, ECO:0007744|PDB:2Z49,
FT                   ECO:0007744|PDB:3W9T"
FT   BINDING         239
FT                   /ligand="Ca(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29108"
FT                   /ligand_label="4"
FT                   /evidence="ECO:0000269|PubMed:15194688,
FT                   ECO:0000269|PubMed:17977832, ECO:0000269|PubMed:24652284,
FT                   ECO:0007744|PDB:1VCL, ECO:0007744|PDB:2Z48,
FT                   ECO:0007744|PDB:2Z49, ECO:0007744|PDB:3W9T"
FT   BINDING         266..269
FT                   /ligand="D-galactose"
FT                   /ligand_id="ChEBI:CHEBI:4139"
FT                   /evidence="ECO:0000269|PubMed:17977832,
FT                   ECO:0000269|PubMed:24652284, ECO:0007744|PDB:2Z48,
FT                   ECO:0007744|PDB:2Z49, ECO:0007744|PDB:3W9T"
FT   BINDING         266
FT                   /ligand="Ca(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29108"
FT                   /ligand_label="5"
FT                   /evidence="ECO:0000269|PubMed:15194688,
FT                   ECO:0000269|PubMed:17977832, ECO:0000269|PubMed:24652284,
FT                   ECO:0007744|PDB:1VCL, ECO:0007744|PDB:2Z48,
FT                   ECO:0007744|PDB:2Z49, ECO:0007744|PDB:3W9T"
FT   BINDING         267
FT                   /ligand="Ca(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29108"
FT                   /ligand_label="5"
FT                   /evidence="ECO:0000269|PubMed:15194688,
FT                   ECO:0000269|PubMed:17977832, ECO:0000269|PubMed:24652284,
FT                   ECO:0007744|PDB:1VCL, ECO:0007744|PDB:2Z48,
FT                   ECO:0007744|PDB:2Z49, ECO:0007744|PDB:3W9T"
FT   BINDING         269
FT                   /ligand="Ca(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29108"
FT                   /ligand_label="5"
FT                   /evidence="ECO:0000269|PubMed:15194688,
FT                   ECO:0000269|PubMed:17977832, ECO:0000269|PubMed:24652284,
FT                   ECO:0007744|PDB:1VCL, ECO:0007744|PDB:2Z48,
FT                   ECO:0007744|PDB:2Z49, ECO:0007744|PDB:3W9T"
FT   BINDING         275
FT                   /ligand="Mg(2+)"
FT                   /ligand_id="ChEBI:CHEBI:18420"
FT                   /ligand_label="2"
FT                   /evidence="ECO:0000269|PubMed:15194688,
FT                   ECO:0000269|PubMed:17977832, ECO:0000269|PubMed:24652284,
FT                   ECO:0007744|PDB:1VCL, ECO:0007744|PDB:2Z48,
FT                   ECO:0007744|PDB:2Z49, ECO:0007744|PDB:3W9T"
FT   BINDING         276
FT                   /ligand="Mg(2+)"
FT                   /ligand_id="ChEBI:CHEBI:18420"
FT                   /ligand_label="2"
FT                   /evidence="ECO:0000269|PubMed:15194688,
FT                   ECO:0000269|PubMed:17977832, ECO:0000269|PubMed:24652284,
FT                   ECO:0007744|PDB:1VCL, ECO:0007744|PDB:2Z48,
FT                   ECO:0007744|PDB:2Z49, ECO:0007744|PDB:3W9T"
FT   BINDING         279..282
FT                   /ligand="D-galactose"
FT                   /ligand_id="ChEBI:CHEBI:4139"
FT                   /evidence="ECO:0000269|PubMed:17977832,
FT                   ECO:0000269|PubMed:24652284, ECO:0007744|PDB:2Z48,
FT                   ECO:0007744|PDB:2Z49, ECO:0007744|PDB:3W9T"
FT   BINDING         286
FT                   /ligand="Ca(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29108"
FT                   /ligand_label="5"
FT                   /evidence="ECO:0000269|PubMed:15194688,
FT                   ECO:0000269|PubMed:17977832, ECO:0000269|PubMed:24652284,
FT                   ECO:0007744|PDB:1VCL, ECO:0007744|PDB:2Z48,
FT                   ECO:0007744|PDB:2Z49, ECO:0007744|PDB:3W9T"
FT   BINDING         286
FT                   /ligand="D-galactose"
FT                   /ligand_id="ChEBI:CHEBI:4139"
FT                   /evidence="ECO:0000269|PubMed:17977832,
FT                   ECO:0000269|PubMed:24652284, ECO:0007744|PDB:2Z48,
FT                   ECO:0007744|PDB:2Z49, ECO:0007744|PDB:3W9T"
FT   MOD_RES         11
FT                   /note="Pyrrolidone carboxylic acid"
FT                   /evidence="ECO:0000269|PubMed:10561549,
FT                   ECO:0000269|PubMed:15194688"
FT   DISULFID        14..59
FT                   /evidence="ECO:0000269|PubMed:15194688,
FT                   ECO:0000269|PubMed:17977832, ECO:0000269|PubMed:24652284,
FT                   ECO:0007744|PDB:1VCL, ECO:0007744|PDB:2Z48,
FT                   ECO:0007744|PDB:2Z49, ECO:0007744|PDB:3W9T"
FT   DISULFID        31..48
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00174,
FT                   ECO:0000269|PubMed:15194688, ECO:0000269|PubMed:17977832,
FT                   ECO:0000269|PubMed:24652284, ECO:0007744|PDB:1VCL,
FT                   ECO:0007744|PDB:2Z48, ECO:0007744|PDB:2Z49,
FT                   ECO:0007744|PDB:3W9T"
FT   DISULFID        72..88
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00174,
FT                   ECO:0000269|PubMed:15194688, ECO:0000269|PubMed:17977832,
FT                   ECO:0000269|PubMed:24652284, ECO:0007744|PDB:1VCL,
FT                   ECO:0007744|PDB:2Z48, ECO:0007744|PDB:2Z49,
FT                   ECO:0007744|PDB:3W9T"
FT   DISULFID        129..146
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00174,
FT                   ECO:0000269|PubMed:15194688, ECO:0000269|PubMed:17977832,
FT                   ECO:0000269|PubMed:24652284, ECO:0007744|PDB:1VCL,
FT                   ECO:0007744|PDB:2Z48, ECO:0007744|PDB:2Z49,
FT                   ECO:0007744|PDB:3W9T"
FT   DISULFID        176..193
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00174,
FT                   ECO:0000269|PubMed:15194688, ECO:0000269|PubMed:17977832,
FT                   ECO:0000269|PubMed:24652284, ECO:0007744|PDB:1VCL,
FT                   ECO:0007744|PDB:2Z48, ECO:0007744|PDB:2Z49,
FT                   ECO:0007744|PDB:3W9T"
FT   DISULFID        217..234
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00174,
FT                   ECO:0000269|PubMed:15194688, ECO:0000269|PubMed:17977832,
FT                   ECO:0000269|PubMed:24652284, ECO:0007744|PDB:1VCL,
FT                   ECO:0007744|PDB:2Z48, ECO:0007744|PDB:2Z49,
FT                   ECO:0007744|PDB:3W9T"
FT   DISULFID        249..254
FT                   /evidence="ECO:0000269|PubMed:15194688,
FT                   ECO:0000269|PubMed:17977832, ECO:0000269|PubMed:24652284,
FT                   ECO:0007744|PDB:1VCL, ECO:0007744|PDB:2Z48,
FT                   ECO:0007744|PDB:2Z49, ECO:0007744|PDB:3W9T"
FT   DISULFID        264..281
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00174,
FT                   ECO:0000269|PubMed:15194688, ECO:0000269|PubMed:17977832,
FT                   ECO:0000269|PubMed:24652284, ECO:0007744|PDB:1VCL,
FT                   ECO:0007744|PDB:2Z48, ECO:0007744|PDB:2Z49,
FT                   ECO:0007744|PDB:3W9T"
FT   DISULFID        308..390
FT                   /evidence="ECO:0000269|PubMed:15194688,
FT                   ECO:0000269|PubMed:17977832, ECO:0000269|PubMed:24652284,
FT                   ECO:0007744|PDB:1VCL, ECO:0007744|PDB:2Z48,
FT                   ECO:0007744|PDB:2Z49, ECO:0007744|PDB:3W9T"
FT   DISULFID        377..416
FT                   /evidence="ECO:0000269|PubMed:15194688,
FT                   ECO:0000269|PubMed:17977832, ECO:0000269|PubMed:24652284,
FT                   ECO:0007744|PDB:1VCL, ECO:0007744|PDB:2Z48,
FT                   ECO:0007744|PDB:2Z49, ECO:0007744|PDB:3W9T"
FT   DISULFID        425..439
FT                   /evidence="ECO:0000269|PubMed:15194688,
FT                   ECO:0000269|PubMed:17977832, ECO:0000269|PubMed:24652284,
FT                   ECO:0007744|PDB:1VCL, ECO:0007744|PDB:2Z48,
FT                   ECO:0007744|PDB:2Z49, ECO:0007744|PDB:3W9T"
FT   DISULFID        431..436
FT                   /evidence="ECO:0000269|PubMed:15194688,
FT                   ECO:0000269|PubMed:17977832, ECO:0000269|PubMed:24652284,
FT                   ECO:0007744|PDB:1VCL, ECO:0007744|PDB:2Z48,
FT                   ECO:0007744|PDB:2Z49, ECO:0007744|PDB:3W9T"
FT   MUTAGEN         26
FT                   /note="Y->A: Weak N-acetylgalactosamine binding."
FT                   /evidence="ECO:0000269|PubMed:17977832"
FT   MUTAGEN         33
FT                   /note="D->A: Loss of N-acetylgalactosamine binding."
FT                   /evidence="ECO:0000269|PubMed:17977832"
FT   MUTAGEN         53
FT                   /note="D->A: Loss of N-acetylgalactosamine binding."
FT                   /evidence="ECO:0000269|PubMed:17977832"
FT   MUTAGEN         54
FT                   /note="Q->A: Loss of N-acetylgalactosamine binding."
FT                   /evidence="ECO:0000269|PubMed:17977832"
FT   MUTAGEN         55
FT                   /note="Q->A: Strongly decreased hemolytic activity compared
FT                   to the wild-type protein. No effect on
FT                   N-acetylgalactosamine binding."
FT                   /evidence="ECO:0000269|PubMed:17977832,
FT                   ECO:0000269|PubMed:23583369"
FT   MUTAGEN         315
FT                   /note="S->A: No effect on lactose binding."
FT                   /evidence="ECO:0000269|PubMed:23583369"
FT   MUTAGEN         325
FT                   /note="S->A: No effect on lactose binding."
FT                   /evidence="ECO:0000269|PubMed:23583369"
FT   MUTAGEN         332
FT                   /note="V->A: Alterations in oligomer formation and in
FT                   hemolytic activity; when associated with A-334 and A-336.
FT                   Alterations in oligomer formation and hemolytic activity;
FT                   when associated with A-334; A-336; A-351; A-353 and A-355."
FT                   /evidence="ECO:0000269|PubMed:17965430,
FT                   ECO:0000269|PubMed:19356139"
FT   MUTAGEN         334
FT                   /note="V->A: Alterations in oligomer formation and in
FT                   hemolytic activity; when associated with A-332 and A-336.
FT                   Alterations in oligomer formation and in hemolytic
FT                   activity; when associated with A-332; A-336; A-351; A-353
FT                   and A-355."
FT                   /evidence="ECO:0000269|PubMed:17965430,
FT                   ECO:0000269|PubMed:19356139"
FT   MUTAGEN         336
FT                   /note="V->A: Alterations in oligomer formation and in
FT                   hemolytic activity; when associated with A-332 and A-334.
FT                   Alterations in oligomer formation and in hemolytic
FT                   activity; when associated with A-332; A-334; A-351; A-353
FT                   and A-355."
FT                   /evidence="ECO:0000269|PubMed:17965430,
FT                   ECO:0000269|PubMed:19356139"
FT   MUTAGEN         340
FT                   /note="I->A: No effect on oligomerization. No effect on
FT                   lactose binding."
FT                   /evidence="ECO:0000269|PubMed:23583369"
FT   MUTAGEN         342
FT                   /note="K->A: No effect on lactose binding. Decreased
FT                   antibacterial activity toward Gram-positive bacteria
FT                   S.aureus IFO 12732."
FT                   /evidence="ECO:0000269|PubMed:14999010,
FT                   ECO:0000269|PubMed:23583369"
FT   MUTAGEN         342
FT                   /note="K->R: Increased antibacterial activity toward
FT                   Gram-positive bacteria S.aureus IFO 12732 and increased
FT                   permeability of the S.aureus cell membrane; when associated
FT                   with R-348; R-354 and R-361."
FT                   /evidence="ECO:0000269|PubMed:14999010"
FT   MUTAGEN         344
FT                   /note="V->L: Increased antibacterial activity toward
FT                   Gram-negative bacteria E.coli ATCC 43827 and P.aeruginosa
FT                   ATCC 27853, and toward Gram-positive bacteria S.aureus IFO
FT                   12732 and B.subtilis IFO 3134 including increased
FT                   permeability of the S.aureus cell membrane; when associated
FT                   with L-351; L-353 and L-355."
FT                   /evidence="ECO:0000269|PubMed:14999010"
FT   MUTAGEN         345
FT                   /note="I->A: Partial oligomerization. No effect on lactose
FT                   binding."
FT                   /evidence="ECO:0000269|PubMed:23583369"
FT   MUTAGEN         348
FT                   /note="K->A: Decreased antibacterial activity toward
FT                   Gram-positive bacteria S.aureus IFO 12732. Markedly
FT                   decreased hemolytic activity compared to the wild-type
FT                   protein. No effect on lactose binding."
FT                   /evidence="ECO:0000269|PubMed:14999010,
FT                   ECO:0000269|PubMed:23583369"
FT   MUTAGEN         348
FT                   /note="K->R: Increased antibacterial activity toward
FT                   Gram-positive bacteria S.aureus IFO 12732 and increased
FT                   permeability of the S.aureus cell membrane; when associated
FT                   with R-342; R-354 and R-361."
FT                   /evidence="ECO:0000269|PubMed:14999010"
FT   MUTAGEN         350
FT                   /note="S->A: No effect on lactose binding."
FT                   /evidence="ECO:0000269|PubMed:23583369"
FT   MUTAGEN         351
FT                   /note="V->A: Alterations in oligomer formation and in
FT                   hemolytic activity; when associated with A-332; A-334;
FT                   A-336; A-353 and A-355. Alterations in oligomer formation
FT                   and in hemolytic activity; when associated with A-353 and
FT                   A-355."
FT                   /evidence="ECO:0000269|PubMed:17965430,
FT                   ECO:0000269|PubMed:19356139"
FT   MUTAGEN         351
FT                   /note="V->L: Increased antibacterial activity toward
FT                   Gram-negative bacteria E.coli ATCC 43827 and P.aeruginosa
FT                   ATCC 27853, and toward Gram-positive bacteria S.aureus IFO
FT                   12732 and B.subtilis IFO 3134 including increased
FT                   permeability of the S.aureus cell membrane; when associated
FT                   with L-344; L-353 and L-355."
FT                   /evidence="ECO:0000269|PubMed:14999010"
FT   MUTAGEN         353
FT                   /note="V->A: Alterations in oligomer formation and in
FT                   hemolytic activity; when associated with A-332; A-334;
FT                   A-336; A-351 and A-355. Alterations in oligomer formation
FT                   and in hemolytic activity; when associated with A-351 and
FT                   A-355."
FT                   /evidence="ECO:0000269|PubMed:17965430,
FT                   ECO:0000269|PubMed:19356139"
FT   MUTAGEN         353
FT                   /note="V->L: Increased antibacterial activity toward
FT                   Gram-negative bacteria E.coli ATCC 43827 and P.aeruginosa
FT                   ATCC 27853, and toward Gram-positive bacteria S.aureus IFO
FT                   12732 and B.subtilis IFO 3134 including increased
FT                   permeability of the S.aureus cell membrane; when associated
FT                   with L-344; L-351 and L-355."
FT                   /evidence="ECO:0000269|PubMed:14999010"
FT   MUTAGEN         354
FT                   /note="K->A: Decreased antibacterial activity toward
FT                   Gram-positive bacteria S.aureus IFO 12732. Markedly
FT                   increased hemolytic activity compared to the wild-type
FT                   protein. No effect on lactose binding."
FT                   /evidence="ECO:0000269|PubMed:14999010,
FT                   ECO:0000269|PubMed:23583369"
FT   MUTAGEN         354
FT                   /note="K->R: Increased antibacterial activity toward
FT                   Gram-positive bacteria S.aureus IFO 12732 and increased
FT                   permeability of the S.aureus cell membrane; when associated
FT                   with R-342; R-348 and R-361."
FT                   /evidence="ECO:0000269|PubMed:14999010"
FT   MUTAGEN         355
FT                   /note="V->A: No effect on lactose binding. Alterations in
FT                   oligomer formation and in hemolytic activity; when
FT                   associated with A-332; A-334; A-336; A-351 and A-353.
FT                   Alterations in oligomer formation and in hemolytic
FT                   activity; when associated with A-351 and A-353."
FT                   /evidence="ECO:0000269|PubMed:17965430,
FT                   ECO:0000269|PubMed:19356139, ECO:0000269|PubMed:23583369"
FT   MUTAGEN         355
FT                   /note="V->L: Increased antibacterial activity toward
FT                   Gram-negative bacteria E.coli ATCC 43827 and P.aeruginosa
FT                   ATCC 27853, and toward Gram-positive bacteria S.aureus IFO
FT                   12732 and B.subtilis IFO 3134 including increased
FT                   permeability of the S.aureus cell membrane; when associated
FT                   with L-344; L-351 and L-353."
FT                   /evidence="ECO:0000269|PubMed:14999010"
FT   MUTAGEN         360
FT                   /note="S->A: No effect on lactose binding."
FT                   /evidence="ECO:0000269|PubMed:23583369"
FT   MUTAGEN         361
FT                   /note="K->A: Decreased antibacterial activity toward
FT                   Gram-positive bacteria S.aureus IFO 12732. Markedly
FT                   increased hemolytic activity compared to the wild-type
FT                   protein. No effect on lactose binding."
FT                   /evidence="ECO:0000269|PubMed:14999010,
FT                   ECO:0000269|PubMed:23545649, ECO:0000269|PubMed:23583369"
FT   MUTAGEN         361
FT                   /note="K->R: Increased antibacterial activity toward
FT                   Gram-positive bacteria S.aureus IFO 12732 and increased
FT                   permeability of the S.aureus cell membrane; when associated
FT                   with R-342; R-348 and R-354."
FT                   /evidence="ECO:0000269|PubMed:14999010"
FT   MUTAGEN         365
FT                   /note="N->A: No effect on lactose binding."
FT                   /evidence="ECO:0000269|PubMed:23583369"
FT   MUTAGEN         375
FT                   /note="Y->A: No effect on lactose binding."
FT                   /evidence="ECO:0000269|PubMed:23583369"
FT   MUTAGEN         381
FT                   /note="D->A: Alterations in hemolytic activity compared to
FT                   the wild-type protein. No effect on lactose binding."
FT                   /evidence="ECO:0000269|PubMed:23583369,
FT                   ECO:0000269|PubMed:27101707"
FT   MUTAGEN         381
FT                   /note="D->K: Almost no hemolytic activity."
FT                   /evidence="ECO:0000269|PubMed:27101707"
FT   MUTAGEN         381
FT                   /note="D->R: 20% of the hemolytic activity of that of the
FT                   wild-type protein."
FT                   /evidence="ECO:0000269|PubMed:27101707"
FT   MUTAGEN         385
FT                   /note="E->A: No effect on lactose binding."
FT                   /evidence="ECO:0000269|PubMed:23583369"
FT   MUTAGEN         388
FT                   /note="R->A: Strongly decreased hemolytic activity compared
FT                   to the wild-type protein. No effect on lactose binding."
FT                   /evidence="ECO:0000269|PubMed:23583369"
FT   MUTAGEN         405
FT                   /note="D->A: No effect on lactose binding."
FT                   /evidence="ECO:0000269|PubMed:23583369"
FT   MUTAGEN         407
FT                   /note="L->A: No effect on oligomerization. No effect on
FT                   lactose binding."
FT                   /evidence="ECO:0000269|PubMed:23583369"
FT   MUTAGEN         413
FT                   /note="I->A: No effect on oligomerization. No effect on
FT                   lactose binding."
FT                   /evidence="ECO:0000269|PubMed:23583369"
FT   MUTAGEN         415
FT                   /note="K->A: 3.6-fold higher hemolytic activity compared to
FT                   the wild-type protein. No effect on oligomerization. No
FT                   effect on lactose binding."
FT                   /evidence="ECO:0000269|PubMed:23583369,
FT                   ECO:0000269|PubMed:27101707"
FT   MUTAGEN         415
FT                   /note="K->E: Markedly decreased hemolytic activity compared
FT                   to the wild-type protein. No effect on lactose binding."
FT                   /evidence="ECO:0000269|PubMed:27101707"
FT   MUTAGEN         415
FT                   /note="K->L: Autoaggregates and cannot be refolded to a
FT                   soluble form."
FT                   /evidence="ECO:0000269|PubMed:27101707"
FT   MUTAGEN         415
FT                   /note="K->R: Markedly decreased hemolytic activity compared
FT                   to the wild-type protein. No effect on lactose binding."
FT                   /evidence="ECO:0000269|PubMed:27101707"
FT   MUTAGEN         415
FT                   /note="K->S: Markedly increased hemolytic activity compared
FT                   to the wild-type protein. No effect on lactose binding."
FT                   /evidence="ECO:0000269|PubMed:27101707"
FT   MUTAGEN         418
FT                   /note="R->A: Markedly decreased hemolytic activity compared
FT                   to the wild-type protein. No effect on lactose binding."
FT                   /evidence="ECO:0000269|PubMed:23583369"
FT   MUTAGEN         430
FT                   /note="K->A: Markedly increased hemolytic activity compared
FT                   to the wild-type protein. No effect on lactose binding."
FT                   /evidence="ECO:0000269|PubMed:23583369"
FT   MUTAGEN         435
FT                   /note="D->A: Markedly increased hemolytic activity compared
FT                   to the wild-type protein. No effect on lactose binding."
FT                   /evidence="ECO:0000269|PubMed:23583369"
FT   CONFLICT        107
FT                   /note="A -> T (in Ref. 1; AA sequence)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        156
FT                   /note="I -> V (in Ref. 1; AA sequence)"
FT                   /evidence="ECO:0000305"
FT   STRAND          16..21
FT                   /evidence="ECO:0007829|PDB:1VCL"
FT   STRAND          23..25
FT                   /evidence="ECO:0007829|PDB:1VCL"
FT   TURN            26..28
FT                   /evidence="ECO:0007829|PDB:1VCL"
FT   STRAND          31..39
FT                   /evidence="ECO:0007829|PDB:1VCL"
FT   STRAND          41..46
FT                   /evidence="ECO:0007829|PDB:1VCL"
FT   HELIX           52..54
FT                   /evidence="ECO:0007829|PDB:1VCL"
FT   STRAND          55..59
FT                   /evidence="ECO:0007829|PDB:1VCL"
FT   STRAND          64..87
FT                   /evidence="ECO:0007829|PDB:1VCL"
FT   STRAND          91..93
FT                   /evidence="ECO:0007829|PDB:1VCL"
FT   HELIX           96..98
FT                   /evidence="ECO:0007829|PDB:1VCL"
FT   STRAND          100..109
FT                   /evidence="ECO:0007829|PDB:1VCL"
FT   STRAND          115..123
FT                   /evidence="ECO:0007829|PDB:1VCL"
FT   TURN            124..126
FT                   /evidence="ECO:0007829|PDB:1VCL"
FT   STRAND          129..137
FT                   /evidence="ECO:0007829|PDB:1VCL"
FT   STRAND          139..144
FT                   /evidence="ECO:0007829|PDB:1VCL"
FT   HELIX           150..152
FT                   /evidence="ECO:0007829|PDB:1VCL"
FT   STRAND          154..156
FT                   /evidence="ECO:0007829|PDB:1VCL"
FT   STRAND          162..170
FT                   /evidence="ECO:0007829|PDB:1VCL"
FT   TURN            171..173
FT                   /evidence="ECO:0007829|PDB:1VCL"
FT   STRAND          176..184
FT                   /evidence="ECO:0007829|PDB:1VCL"
FT   STRAND          186..191
FT                   /evidence="ECO:0007829|PDB:1VCL"
FT   HELIX           197..199
FT                   /evidence="ECO:0007829|PDB:1VCL"
FT   STRAND          201..204
FT                   /evidence="ECO:0007829|PDB:1VCL"
FT   STRAND          209..211
FT                   /evidence="ECO:0007829|PDB:1VCL"
FT   TURN            212..214
FT                   /evidence="ECO:0007829|PDB:1VCL"
FT   STRAND          217..225
FT                   /evidence="ECO:0007829|PDB:1VCL"
FT   STRAND          227..232
FT                   /evidence="ECO:0007829|PDB:1VCL"
FT   HELIX           238..240
FT                   /evidence="ECO:0007829|PDB:1VCL"
FT   HELIX           246..248
FT                   /evidence="ECO:0007829|PDB:1VCL"
FT   TURN            259..261
FT                   /evidence="ECO:0007829|PDB:1VCL"
FT   STRAND          264..272
FT                   /evidence="ECO:0007829|PDB:1VCL"
FT   STRAND          274..279
FT                   /evidence="ECO:0007829|PDB:1VCL"
FT   HELIX           285..287
FT                   /evidence="ECO:0007829|PDB:1VCL"
FT   STRAND          289..292
FT                   /evidence="ECO:0007829|PDB:1VCL"
FT   STRAND          300..309
FT                   /evidence="ECO:0007829|PDB:1VCL"
FT   STRAND          315..318
FT                   /evidence="ECO:0007829|PDB:1VCL"
FT   STRAND          321..323
FT                   /evidence="ECO:0007829|PDB:1VCL"
FT   HELIX           330..342
FT                   /evidence="ECO:0007829|PDB:1VCL"
FT   HELIX           353..364
FT                   /evidence="ECO:0007829|PDB:1VCL"
FT   STRAND          373..376
FT                   /evidence="ECO:0007829|PDB:1VCL"
FT   STRAND          383..385
FT                   /evidence="ECO:0007829|PDB:1VCL"
FT   STRAND          387..400
FT                   /evidence="ECO:0007829|PDB:1VCL"
FT   TURN            401..404
FT                   /evidence="ECO:0007829|PDB:1VCL"
FT   STRAND          405..410
FT                   /evidence="ECO:0007829|PDB:1VCL"
FT   STRAND          414..418
FT                   /evidence="ECO:0007829|PDB:1VCL"
FT   STRAND          429..433
FT                   /evidence="ECO:0007829|PDB:1VCL"
FT   STRAND          438..440
FT                   /evidence="ECO:0007829|PDB:1VCL"
SQ   SEQUENCE   442 AA;  48456 MW;  3E47C608446D40EC CRC64;
     MVSLVPCGFA QVLCTNPLDI GELRNYKSKQ CVDIVGNQGS GNIATHDCDG LSDQQIIMCG
     DGTIRNEARN YCFTPDGSGN ANVMSSPCTL YPEIPSSQRW RLGRKKAFTD NGGIEQVATE
     IINLASGKCL DVEGSDGTGD IGVYDCQNLD DQYFYIRSRG PELFYGRLRN EKSDLCLDVE
     GSEGKGNVLM YSCEDNLDQW FRYYENGEIV NAKQGMCLDV EGSDGSGNVG IYRCDDLRDQ
     MWSRPNAYCN GDYCSFLNKE SNKCLDVSGD QGTGDVGTWQ CDGLPDQRFK WVFDDWEVPT
     ATWNMVGCDQ NGKVSQQISN TISFSSTVTA GVAVEVSSTI EKGVIFAKAS VSVKVTASLS
     KAWTNSQSGT TAITYTCDNY DSDEEFTRGC MWQLAIETTE VKSGDLLVWN PQIIKCTRSN
     TAPGCAPFTK CANEDCTFCT DI
//
